Repare Therapeutics Statistics
Total Valuation
RPTX has a market cap or net worth of $140.92 million. The enterprise value is -$65.03 million.
Important Dates
The next estimated earnings date is Thursday, November 7, 2024, before market open.
| Earnings Date | Nov 7, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
RPTX has 42.45 million shares outstanding. The number of shares has increased by 0.51% in one year.
| Shares Outstanding | 42.45M |
| Shares Change (YoY) | +0.51% |
| Shares Change (QoQ) | -3.59% |
| Owned by Insiders (%) | 0.99% |
| Owned by Institutions (%) | 36.43% |
| Float | 20.11M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.04 |
| Forward PS | 8.30 |
| PB Ratio | 0.69 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.27, with a Debt / Equity ratio of 0.01.
| Current Ratio | 7.27 |
| Quick Ratio | 7.08 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -30.52% and return on invested capital (ROIC) is -26.27%.
| Return on Equity (ROE) | -30.52% |
| Return on Assets (ROA) | -22.30% |
| Return on Capital (ROIC) | -26.27% |
| Revenue Per Employee | $383,704 |
| Profits Per Employee | -$382,799 |
| Employee Count | 179 |
| Asset Turnover | 0.26 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -15.15M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -70.36% in the last 52 weeks. The beta is 0.70, so RPTX's price volatility has been lower than the market average.
| Beta (5Y) | 0.70 |
| 52-Week Price Change | -70.36% |
| 50-Day Moving Average | 3.27 |
| 200-Day Moving Average | 4.64 |
| Relative Strength Index (RSI) | 57.55 |
| Average Volume (20 Days) | 105,042 |
Short Selling Information
The latest short interest is 721,297, so 1.70% of the outstanding shares have been sold short.
| Short Interest | 721,297 |
| Short Previous Month | 741,690 |
| Short % of Shares Out | 1.70% |
| Short % of Float | 3.59% |
| Short Ratio (days to cover) | 8.08 |
Income Statement
In the last 12 months, RPTX had revenue of $68.68 million and -$68.52 million in losses. Loss per share was -$1.62.
| Revenue | 68.68M |
| Gross Profit | -59.95M |
| Operating Income | -95.79M |
| Pretax Income | -83.68M |
| Net Income | -68.52M |
| EBITDA | -93.80M |
| EBIT | -95.79M |
| Loss Per Share | -$1.62 |
Full Income StatementBalance Sheet
The company has $208.12 million in cash and $2.18 million in debt, giving a net cash position of $205.95 million or $4.85 per share.
| Cash & Cash Equivalents | 208.12M |
| Total Debt | 2.18M |
| Net Cash | 205.95M |
| Net Cash Per Share | $4.85 |
| Equity (Book Value) | 203.68M |
| Book Value Per Share | 4.80 |
| Working Capital | 197.09M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$79.61 million and capital expenditures -$398,000, giving a free cash flow of -$80.01 million.
| Operating Cash Flow | -79.61M |
| Capital Expenditures | -398,000 |
| Free Cash Flow | -80.01M |
| FCF Per Share | -$1.88 |
Full Cash Flow StatementMargins
Gross margin is -87.28%, with operating and profit margins of -139.46% and -99.76%.
| Gross Margin | -87.28% |
| Operating Margin | -139.46% |
| Pretax Margin | -121.83% |
| Profit Margin | -99.76% |
| EBITDA Margin | -136.56% |
| EBIT Margin | -139.46% |
| FCF Margin | -116.49% |
Dividends & Yields
RPTX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.51% |
| Shareholder Yield | -0.51% |
| Earnings Yield | -48.62% |
| FCF Yield | -56.77% |
Analyst Forecast
The average price target for RPTX is $17.33, which is 421.99% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $17.33 |
| Price Target Difference | 421.99% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | 12.03% |
| EPS Growth Forecast (5Y) | -18.57% |
Stock ForecastsStock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
RPTX has an Altman Z-Score of 3.01 and a Piotroski F-Score of 1.
| Altman Z-Score | 3.01 |
| Piotroski F-Score | 1 |